ABSTRACT
INTRODUCTION
Nevertheless, the highly efficient geneexpression and noninva sive natureof adenovirus administration does have advantages for Recombinant adenoviruses have useful features for gene clinicalapplication. A life-threatening acute illness is often assodelivery in cases of in vivo gene transfer (Kremer and dated withmetabolic liverdiseases, suchas organic acidemia or Perricaudet, 1995) . Transduced genes areevident in a wide spec-ureacycle disorders; hence, genetransfer by recombinant aden- Medicine, Kumamoto 860, Japan. department ofGenetics, Central Institute for Experimental Animals, 1430 Nogawa, Miyamae, Kawasaki 216, Japan. laboratory ofMolecular Genetics, Institute ofMedical Science, The University ofTokyo, Tokyo 108, Japan. department ofMolecular Embryology, Institute ofDevelopment, Aging and Cancer, Tohoku University, Sendai, Japan. ovirus could be expected to provide alternative treatment, in ad dition to organ transplantation.
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In the present study, we developed an experimental model of gene therapy for defective ketoacid metabolismof tyrosine in he patocytes (Endo et al, , 1995 . In our ongoing related stud ies, we find that recombinant adenovirus with a CAG promoter (modified chicken /3-actin promoter with CMV-IE enhancer) (Miyazaki et al, 1989; Niwa et al, 1991) is effective for ex pressing a foreign gene in livers of mice (Kiwaki et al, 1996) . We used a mouse model for 4-hydroxyphenylpyruvate dioxyge nase (HPD; EC 1.13.11.27) deficiency to assess the usefulness of the adenovirus system for transient gene transfer in hepatocytes. HPD is an enzyme that catabolizes4-hydroxyphenylpyruvate and is present in liver and kidney (Buckthal and Roche, 1987; Fellman, 1987; Lindstedt and Odelhog, 1987) . Homogentisic acid is pro duced from 4-hydroxyphenylpyruvic acid by this enzyme; the re action involvesdecarboxylation, oxidation,and rearrangement. A deficiency of HPD results in type 3 tyrosinemia (McKusick 276710), an autosomal recessive disorder characterized by ele vated blood concentrations of tyrosine and massive excretion into urine of 4-hydroxyphenylpyruvic acid, 4-hydroxyphenylIactic acid, and 4-hydroxyphenylacetic acid (Endo et al., 1983) . Patients with this disorder are mentally retarded, but there is no liver dam age (Endo et al, 1983; Giardinie/a/., 1983; Mitchell et al, 1995) . Mouse strain /// is a model for human tyrosinemia type 3 and is characterized by mild elevation of blood tyrosine and the absence of visceral injuries Katoh et al, 1991) . There is a C-to-T transition at +7 nucleotide on exon 7 of the HPD gene on chromosome 5 of the /// mouse, resulting in the premature ter mination of translation (Endo et al, 1995) . Using this mouse model, expression of the functional HPD gene in hepatocytes is expected to normalize blood tyrosine levels.
MATERIALS AND METHODS

Construction of recombinant adenoviral vector
A replication-defective recombinant adenovirus, human adenovirus type 5 (Ad5) lacking the El A, El B, and E3 re gions and bearing human HPD expression unit at the Eldeleted region was prepared as described in Miyake et al (1996) . Transcription orientation of the expression cassette is leftward, opposite the original orientation of El A and E1B genes. A Bam Hl-Sal I fragment of human HPD cDNA was prepared as described by Endo et al. (1992) and inserted. Expression of HPD is driven by the CAG promoter, which consists of the cytomegalovirus (CMV) immediate early (IE) enhancer and a chicken j3-actin/rabbit /3-globin hybrid pro moter and containing rabbit j8-globin 3'-flanking sequences, including a polyadenylation signal (Miyazaki et al, 1989; Niwa etal, 1991) . For the control experiments, we used a re combinant adenoviral vector bearing the human ornithine transcarbamylase (OTC) cDNA (AdexCAGhOTC), as de scribed by Kiwaki et al (1996) . The adenovirus was purified and titrated, as described in Kanegae et al (1994) .
Animals
We previously described the mouse strain ///, in which he patic HPD activity and the protein are absent (Endo etal, 1991;  KUBO ET AL. Katoh et al, 1991) . These mice have elevated levels of blood tyrosine, the range being between 1,100 and 1,656 yM (under 300 fiM in BALB/c control mice) and they excrete massive amounts of derivatives into their urine.This phenotype is trans mitted through an autosomal recessive mode of inheritance, and there is no evidence of liver or kidney damage, findings simi lar to those for human type 3 tyrosinemia.
Blood tyrosine levels
Blood tyrosine levels were measured in dried blood speci mens, using high-performance liquid chromatography.
Enzyme and protein assay
Livers were homogenized in 50 mM ice-cold potassium phosphate buffer pH 7.4 and centrifuged at 10,000 X g for 20 min. The supernatants were used for the enzyme assay. The ra diochemical assay of HPD was carried out according to Lindblad et al (1977) , with a slight modification (Endo et al, 1983) . Proteins were measured by the dye-binding method us ing a kit from BioRad Laboratories (Richmond, CA).
Electrophoresis and immunoblot for HPD
Liver samples from mousestrain /// were snap-frozen in dry ice, kept at -70°C until use, and then homogenized in ice-cold 50 mM Tris-HCl buffer pH 7.4 followed by centrifugation at 11,000 X g for 15 min at 4°C. The supernatants were subjected to SDS-polyacrylamide gel (10%) electrophoresis (PAGE). Immunoblot for HPD was carried out using antiserum directed to recombinant human HPD. Rabbits were immunized with GST-hHPD for production of the antibody (unpublished data). Preparation of human HPD cDNA was as described (Endo et al, 1992) . Other conditions for SDS-PAGE and immunoblot were as described (Endo et al, 1992) .
DNA analysis
DNA from the /// mice was isolated from whole brain, heart, lung, liver, spleen, kidney, small intestine, colon, testis, and thigh muscle. To evaluate the distribution of recombinant adenovirus, 100 ng of the DNA was used for 30 cycles of PCR (45 sec of denaturation at 94°C, 1 min of annealing at 60°C, and 45 sec of extension at 72°C), using the human-specific primer set located in exon 14 of the human HPD gene (HPD-9, 5'-CTCACTA-GACCTGGAGCCCAATGG-3'; HPDH3'; 5'-GCACCGACA-CACCGACACCGGAGGCA-3').
RNA analysis
Total RNA was isolated from the tissues using ISOGEN (Wako Pure Chemical Industries Ltd., Osaka). Isolated RNAs were treated with DNase, as described elsewhere (Ausubel et al, 1987) .First-strandcDNA was generated from 2 fig of total RNA, using Moloney murine leukemiavirus reversetranscriptase with an oligo(dT) primer. Reverse-transcribed products were ampli fied by 25 cycles of PCR (RT-PCR) (45 sec of denaturation at 94°C, 1 min of annealing at 55°C, and 45 sec of extension at 72°C).The primer set used for the RT-PCR was the human-spe cific HPD primer used for amplification of cDNA analysis, as described above.
ADENOVIRAL GENE THERAPY IN TYROSINEMIA
Total RNA (10 fig) was fractionated through a 1.0% agaroseformaldehyde gel, transferred to nylon membrane, probedwith an Eco Rl-digested fragment (1.2 kb) of human HPD cDNA, and visualized by autoradiography.
Histopathology
For routine hematoxylin-eosin staining, livers were fixed in vivo in circulating 2% neutralized paraformaldehyde solution and then immersed into 10% neutralized formalin for 1 week prior to sectioning and staining.
Primary culture of hepatocytes
Primary culture of hepatocytes obtained from /// mice was prepared as described by Ueno et al (1993) .
RESULTS
In vitro correction in primary hepatocytes derived from the strain III mouse
Primary hepatocytes derived from strain /// mouse were in fected 48 hr after plating with AdexCAGhHPD at m.o.i. 0,1,10, 30, 50, and 100. The cells were harvested, measurements were made of HPD activities, and immunoblots for HPD were pre pared ( Fig. la,b) . Because the subunit of the human HPD is com posed of 392 amino acid residues and the mature enzyme is a homodimerof an identical subunit with Mr43000, effectivegene transfer should result in appearance of the subunit protein. The cultured hepatocytes from /// mice had no protein related to hu man HPD (Fig. la) , such being consistent with observations of the liver (Fig. lb) . Thus, transfer of the recombinantadenovirus resulted in expres sion of functional human HPD in mouse hepatocytes.
Tissue distribution of recombinant adenovirus after injection via the tail vein
The /// mouse was killed 1 week after tail vein infusion of 5.0 X 108 pfuand DNA analysis was performed. Theprimer set used in PCR was designed to amplify the 70-bp fragment corre sponding to the sequences of exon 14 of human HPD cDNA. In a preliminary experiment, we found that this primer set ampli fied the human HPD cDNA sequences,but not mousecDNA se quences. In addition,no sequence was amplifiedwhen mousege nomic DNA was used as a template. We detected specifically amplified 70-bp sequences in all tissues examined exceptthose of brainand testis (Fig.2a) .The amounts of amplified DNAwere predominant in samples from liver, spleen, and thigh muscle.
Expression of HPD mRNA and protein of viral origin
Total RNAs were isolated from several tissues of /// mice infected with AdexCAGhHPD and analyzed from mRNA re- lated to HPD. The RT-PCR analysis of cDNA was carried out using primers that amplify only the human HPD sequence, and revealed that human HPD mRNA is expressed in the liver, lung, spleen, and small intestine (Fig. 2b) . Among these organs, the sample from the liver showed most prominent amplification. The expression of HPD sequences was next analyzed using Northern blots. The results shown in Fig. 2c indicate that the liver expresses notable amounts of human HPD mRNA and trace amounts are expressed in the small intestine. The trans genic expression of human HPD could be distinguished from mouse HPD, since HPD mRNA in the /// mouse is approxi mately 2.1 kb and the human HPD is 1.3 kb. The transgene product, human HPD protein, was detected only in the liver by immunoblot analysis (Fig. 2d) . Because the antibody did not detect cross-reacting protein in the /// mouse liver, the 43-kD protein is of viral origin. The results of protein blot correlated well with those of mRNA blots.
Metabolic correction in III mice
The effect of hepatic human HPD expression in /// mice was investigated by analyzing blood tyrosine levels after intra DNA, total RNA, and protein were isolated and analyzed for brain, heart, lung, liver, spleen, kidney, small intestine, colon, testis, and thigh muscle, as described under Materials and Methods, a. Distribution of human HPD sequence in various tissues. A total of 100 ng of the genomic DNAs were used for PCR amplification of human HPD sequence, using the primary set described in Materials and Methods. A 70-bp DNA fragment represents of human HPD cDNA sequence, At the initial investigation, blood tyrosine levels were deter mined at 1-week intervals (Fig. 3a) . When over 3.0 X IO8 pfu was injected, blood tyrosine levels significantly decreased, reached the normal range (under 300 fxM), and remained at a low level for 2-6 weeks (Fig. 3a) . However, significant changes in blood tyrosine levels were not observed after the second in jection of 5.0 X 108 pfu of AdexCAGhHPD.
Because blood tyrosine levels reached the lowest levels at 1 week after injection, we next investigated earlier phases of metabolic changes in the treated animals. In this experiment, blood samples were taken at 3-hr intervals and analyzed for blood tyrosine following administration of the recombinant virus through the tail vein. The experiments (n = 4) revealed that a significant reduction in blood tyrosine was evident as early as 3 hr after the injection 5.0 X 108 pfu in /// mice (Fig.   3b ). The lowest levels of blood tyrosine were noted 15-24 hr after administration. The control experiments in which either 5.0 X 108 pfu of AdexCAGhOTC (n = 4) or only buffersolu tion (n = 2) was injected into /// mice revealed no significant changes in blood tyrosine. KUBO ET AL. Hepatic HPD activities in tyrosinemic /// mice also signifi cantly increased as early as 3 hr (55.4% of the BALB/c control mice) after the injectionof 5.0 X 108 pfu AdexCAGhHPD (Fig.   4) , reached the highest levels (102.0 and 112.6% on 3 day and 1 week, respectively), then decreased (41.7% at 1 month). Hepatic HPD activities correlated well to blood tyrosine levels (Fig. 4) .
Histological examination of liver from mice injected with vectors
The histology of liver sections obtained from /// mice in jected with5.0 X 108 pfu or 1.0 X 109 pfu wereessentiallysim ilar to those from the untreated /// mice or the /// mice treated with 5.0 X 108 pfu AdexCAGhOTC. 
DISCUSSION
The /// mouse is a well-characterized animal model for hu man type 3 tyrosinemia Katoh et al., 1991) . In these mice, a point mutation in exon 7 of HPD gene causes generation of a premature termination codon and leads to an al tered splicing product in the liver, presumably due to an in creased instability of transcript with a premature termination signal (Endo et al., 1995) . As a consequence of the mutation, HPD activity is absent in livers of these mice, blood tyrosine accumulates, and there is an increased excretion of 4-hydrox yphenylpyruvate into the urine. Because this mouse strain is a model for a genetic defect in oxidation of ketoacids derived from amino acids, hepatic gene therapy to correct the metabolic defect in this mouse model has made available the first exam ple of experimental gene therapy to treat an inherited ketoacid metabolism.
A replication-deficient adenoviral vector that contains hu man HPD cDNA expressed from a CAG promoter was con structed (Miyazaki et al., 1989; Niwa et al., 1991) . Pilot ex periments were performed to determine the dose of virus required to increase HPD enzyme activity significantly in the liver when a vector was infused into the /// mice. We found that the maximally 1.0 X 10''pfu of the recombinant adenovirus containing human HPD resulted in a correction of blood tyro sine levels in these mice, without any definite microscopical liver damage. Thus, the recombinant adenovirus containing hu man HPD can effectively reduce blood tyrosine levels in /// mice, under the maximally tolerated dose.
Our protocol provided a highly specific expression of human HPD in livers of /// mice. This may be partly due to the trans duction efficiency of the recombinant adenovirus given intra venously. Previous studies indicated that the intravenous ad ministration of recombinant virus produced a strong transduc , 1995) . In addition, the functional CAG promoter seemed to contribute to liver-specific expression of the transgene in our experiments. The transgene carried by the aden oviral vector was detected by PCR analysis of cellular DNA in various tissues, and the transcript was detected by RT-PCR in some tissues, including the liver. However, transcript and pro tein products of the transgene in tissues except the liver are too low to detect by Northern or immunoblots respectively. When a recombinant adenovirus AdexCAGhOTC, which carries hu man OTC cDNA instead of human HPD cDNA under the con trol of CAG promoter, was injected into the tail vein of mice, the virus genome was detected in kidney, lung, and muscle, as well as in liver (Kiwaki et al., 1996) . However, RT-PCR analy sis detected the human OTC transcript only in the liver (Kiwaki et al, 1996) . Our previous work also demonstrated that re combinant adenovirus bearing the CAG promoter can express the transgene in cultured cells from various sources, however, the maximum expression was noted in HepG2 cells derived from human hepatocytes (data not shown). Moreover, we found in in vivo and in vitro experiments that an adenoviral vector carrying the CAG promoter is much more effective in ex pressing the transgene in hepatocytes than the vector carrying the SRo-promoter (Kiwaki et al., 1996) . All of our observa tions taken together suggest that the intravenous administration of the adenoviral vector carrying the CAG promoter will likely be a pertinent approach to hepatic gene therapy.
Adenovirus releases DNA into the nucleus of the host cell within 2 hr after binding to cell-surface receptor (Greber et al, 1993) , however little is known of the time required for expres sion of the transgene delivered with use of adenoviral vectors. Therapeutic levels of factor DC were noted 18 hr after admin istration of recombinant adenovirus carrying the Rous-sarcoma virus long terminal repeat (RSV-LTR) promoter in hemophilia B dogs (Kay et al, 1994) . We found a significant reduction in bloodtyrosine as early as 3 hr after the injection 5.0 X 108 pfu into /// mice. This rapid improvement of blood tyrosine levels shows promise for gene therapy in subjects who are acutely ill with the metabolic diseases, such as maple syrup urine disease, which causes acute illness due to accumulation of keto acid and a severe metabolic acidosis. These conditions lead to additional metabolic derangements of hepatocytes and other cells, thus life-saving treatment is a great challenge for physicians. Gene transfer was evident in /// mice as early as 3 hr after infusion of the viral particle, even in case of metabolic defects of ketoacid oxidation.
Patients with an acute illness and who require immediate liver transplantation, may benefit from this gene therapy, espe cially when donor organs are not available.
